대한임상검사과학회지 (Korean Journal of Clinical Laboratory Science)
- 제43권4호
- /
- Pages.150-155
- /
- 2011
- /
- 1738-3544(pISSN)
- /
- 2288-1662(eISSN)
Efficacy of Serum PIVKA-II in the Diagnosis and Follow-up after Treatment of Hepatocellular Carcinoma
- Lee, Sang-Hee (Department of Laboratory Medicine, Ulsan University College of Medicine and Asan Medical Center) ;
- Gu, Gum-Gyoung (Department of Laboratory Medicine, Ulsan University College of Medicine and Asan Medical Center) ;
- Han, Tae-Jin (Department of Laboratory Medicine, Ulsan University College of Medicine and Asan Medical Center) ;
- Paik, Byung-Yoon (Department of Laboratory Medicine, Ulsan University College of Medicine and Asan Medical Center) ;
- Chun, Sail (Department of Laboratory Medicine, Ulsan University College of Medicine and Asan Medical Center) ;
- Min, Won-Ki (Department of Laboratory Medicine, Ulsan University College of Medicine and Asan Medical Center)
- 투고 : 2011.11.08
- 심사 : 2011.12.08
- 발행 : 2011.12.30
초록
It is a very important diagnosis and evalution of Hepatocellular carcinoma (HCC) in Korea where hepatitis B-virus is endemic. Protein induced by vitamin K absence or antagonist II (PIVKA-II) appears to be a useful tumor marker. This study was purposed to investigate usefulness of PIVKA-II in the diagnosis and fallow-up after treatment of HCC. A total of 418 patients were included in 187 patients (44.7%) of HCC, 83 patients (19.9%) of liver cirrhosis, 74 patients (17.7%) of chronic hepatitis and 74 patients (17.7%) of other liver diseases with serum PIVKA-II levels by Hicatch PIVKA-II kit. PIVKA-II level were analysed for difference of groups and the comparison of treatment responses. The sensitivity and specificity of PIVKA-II in the diagnosis of HCC were 80.2%, 87.0% at the cut-off value of 40 mAU/mL. There were statistically significant difference between the HCC and other groups (p<0.001), before and after PIVKA-II levels after treatment in HCC (p<0.001). PIVKA-II can be used as a useful tumor marker for patients with HCC, especially early diagnosis in high risk groups, treatment response assesment and monitoring of recurrence.